Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.560
-0.170 (-3.59%)
At close: Feb 27, 2026, 4:00 PM EST
4.610
+0.050 (1.10%)
After-hours: Feb 27, 2026, 7:31 PM EST
Achieve Life Sciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Achieve Life Sciences stock have an average target of 15.5, with a low estimate of 12 and a high estimate of 19. The average target predicts an increase of 239.91% from the current stock price of 4.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 25, 2025.
Analyst Ratings
The average analyst rating for Achieve Life Sciences stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Initiates $19 | Buy | Initiates | $19 | +316.67% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +163.16% | Aug 21, 2025 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +163.16% | Nov 14, 2024 |
| Raymond James | Raymond James | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +338.60% | Sep 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +141.23% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
17.12M
EPS This Year
-1.28
from -1.24
EPS Next Year
-1.15
from -1.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 29.8M | ||||
| Avg | n/a | 17.1M | ||||
| Low | n/a | 5.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.25 | -0.88 | ||||
| Avg | -1.28 | -1.15 | ||||
| Low | -1.27 | -1.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.